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Abstract
Acute Kidney Injury (AKI), a sudden decline in kidney function, is associated with
increased mortality, morbidity, length of stay, and hospital cost. Since AKI is sometimes
preventable, there is great interest in prediction. Most existing studies consider all
patients and therefore restrict to features available in the first hours of hospitalization.
Here, the focus is instead on rehospitalized patients, a cohort in which rich longitudinal
features from prior hospitalizations can be analyzed. Our objective is to provide a risk
score directly at hospital re-entry. Gradient boosting, penalized logistic regression (with
and without stability selection), and a recurrent neural network are trained on two years
of adult inpatient EHR data (3,387 attributes for 34,505 patients who generated 90,013
training samples with 5,618 cases and 84,395 controls). Predictions are internally
evaluated with 50 iterations of 5-fold grouped cross-validation with special emphasis on
calibration, an analysis of which is performed at the patient as well as hospitalization
level. Error is assessed with respect to diagnosis, race, age, gender, AKI identification
method, and hospital utilization. In an additional experiment, the regularization
penalty is severely increased to induce parsimony and interpretability. Predictors
identified for rehospitalized patients are also reported with a special analysis of
medications that might be modifiable risk factors. Insights from this study might be
used to construct a predictive tool for AKI in rehospitalized patients. An accurate
estimate of AKI risk at hospital entry might serve as a prior for an admitting provider
or another predictive algorithm.
Introduction
Acute kidney injury (AKI) is a sudden decline in kidney function over days, which may
be temporary or permanent [1, 2]. AKI is common in hospitalized patients, with an
estimated incidence of 13% and, importantly, is associated with greatly increased
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morbidity (e.g., long-term dialysis), mortality, length of stay, and hospital cost [3].
Diagnosis of AKI is challenging, as patients are generally asymptomatic and commonly
used biomarkers change over a period of days following injury [4]. Causes of AKI are
generally grouped into decreased renal blood flow (e.g., hypotension due to sepsis or
heart failure), direct renal toxicity (e.g., due to medications, radiocontrast dye, or
bacterial toxins), and urinary outflow obstruction (e.g., bladder outlet obstruction or
kidney stones).
Defining AKI for research purposes, or to assess clinical outcomes, is also challenging.
A variety of definitions exist, primarily based on changes in the concentration of serum
creatinine (sCr). Creatinine is a protein made by muscle and excreted by the kidneys
via glomerular filtration. Serum Cr is inversely proportional to the glomerular filtration
rate (GFR), a true indicator of renal function that is not easily measured. Doubling of
sCr at steady state reflects a 50% decrease in renal function. Consensus definitions for
AKI rely heavily on changes in sCr over time, and include the 2004 RIFLE criteria [1]
(modified in 2007 by the Acute Kidney Injury Network (AKIN) [5]) and the 2012
Kidney Disease: Improving Global Outcomes (KDIGO) [6,7] definitions. The KDIGO
AKI definition, which we use here, combines the RIFLE “Risk” definition with the
AKIN criterion for absolute increase in sCr.
Developing a broadly applicable and accurate risk index for AKI in rehospitalized
patients could have a major impact on hospital care, particularly if it were practical
enough to allow preventive intervention or more intense monitoring from the time of
hospital admission [8]. With early risk identification, a variety of preventive strategies
can be implemented [9]. For example, AKI from radiocontrast dye, chemotherapy, or
aminoglycoside antibiotics can be prevented by altering treatment, administration of
fluids, alternate imaging modalities or close monitoring [10–13]. Given that such
interventions can mitigate severity, AKI prediction is an area of active research, with
recent emphasis on Electronic Health Record (EHR) data [8, 14–16]. Existing studies
generally focus on AKI in the context of cardiac procedures [17–20], critical
illness [21–26], the elderly [27], transplants of the liver [28] and lung [29], and extensive
muscle injury (rhabdomyolysis) [30,31]. Recently, we see predictive systems [15,16,27]
that exploit numerous features from the EHR rather than a small number of manually
picked variables. In existing studies, predictions of AKI risk are made for all
hospitalized patients, many of whom do not have previous hospitalizations. They are
hence restricted to features from the current hospitalization, even when a patient has
more extensive information in the EHR.
To our knowledge, there are no published studies focused explicitly and exclusively
on a large cohort of rehospitalized patients. Focus on this group allows analysis of
longitudinal information from prior hospitalizations (e.g., the number of previous
episodes of AKI, the number of abnormal urea nitrogen (UN) readings, or the number
of loop diuretics administered). Although the subset of rehospitalized patients is a
specific cohort, such an analysis is general as it pertains to all rehospitalized patients.
Since rehospitalized patients have not been studied explicitly in the literature, all
available features from all available time points were analyzed.
In this framework, prior hospitalizations might be considered surrogate “renal stress
tests,” reflecting renal resiliency to injurious events. Conversely, prior hospitalizations
might be renal stressors, diminishing renal reserve. Most previous studies on AKI posit
data models, although some more recent work [16,27] explores predictive algorithms,
distinct from data models [32], as done here. Penalized regression and ensemble
methods were employed to mitigate overfitting. In particular, a decision tree ensemble
classifier constructed with gradient boosting (GBC), which is highly robust to outliers
and well suited to high-dimensional, noisy data [33], was explored along with a recurrent
neural network [34] (LSTM) for time series analysis, and penalized logistic regression
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(LR1) for high-dimensional data where it is believed that only a few features are
relevant [35]. In an additional experiment with the latter, the penalty was increased
severely to induce parsimony and interpretability. New AKI predictors specific to
rehospitalized patients were identified; a special analysis of medication-related
predictors is presented as they may be of interest as potentially modifiable risk factors.
Materials and Methods
Dataset
The research protocol was approved by the University of Rochester Research Subjects
Review Board (RSRB00056930). Research data were coded such that patients could not
be directly identified in compliance with the Department of Health and Human Services
Regulations for the Protection of Human Subjects (45 CFR 46.101(b)(4)). This dataset
is a comprehensive 2-year window into the EHR for informatics and population-health
studies. For this work we excluded all hospitalizations with age at admission < 18 years,
all hospitalizations following a prior hospitalization in which the ICD-9 code for end
stage renal disease (ESRD; 585.9) was assigned. Hospitalizations following a transplant
for ESRD were included. Patients who had undergone dialysis were included, as dialysis
is sometimes performed in the setting of transient AKI, and therefore presence of
dialysis does not indicate permanent renal dysfunction. Multiple hospitalizations were
available for roughly 32% of patients.
The dataset consisted of tables containing administrative, laboratory, and
medication data that was queried respectively from separate billing (Flowcast, IDX
Systems), eRecord (Epic), and pharmacy databases which could be joined on admit id,
which were linked during de-identification. The administrative dataset included
International Classification of Diseases, 9th Revision (ICD-9) diagnosis and procedure
codes, Current Procedural Terminology 4th Edition (CPT-4) procedure codes,
Diagnosis-Related Groupings (DRG) codes, bed locations during hospitalization,
discharge disposition, discharge and admission days, insurance (primary, secondary, and
other), marital status, gender, age, race, and total length of stay. The laboratory
dataset included direct bilirubin, point-of-care creatinine, bicarbonate, chloride, calcium,
anion gap, phosphate, glomerular filtration rate, sCr, urea nitrogen (UN), albumin,
total protein, aspartate and alanine transaminase, hemoglobin, glucose, and glycated
hemoglobin. The pharmacy dataset included, for each medication, description,
pharmacologic class and subclass, and therapeutic class. Table 1 contains abbreviations.
Definitions
Hospitalization: hospitalization was defined as an admission (inpatient) or
administrative status “under observation” (e.g., in the emergency department, but not
admitted to inpatient care). AKI: AKI was defined as the presence of either an
administrative diagnosis code or sCr delta. Administrative ICD9 codes included 584.5
(AKF with lesion of tubular necrosis), 584.6 (AKF with lesion of renal cortical necrosis),
584.7 (AKF with lesion of renal medullary (papillary) necrosis), 584.8 (AKF with other
specified pathological lesion in kidney), or 584.9 (AKF, unspecified). As diagnosis codes
are believed to be specific but not sensitive for AKI [36], they were supplemented with
sCr for patients with available laboratory values. Using KDIGO guidelines [6], diagnosis
was made with a 1.5-fold or greater increase in sCr from baseline within 7 days or 0.3
mg/dL or greater increase in sCr within 48 hours. Baseline sCr for an individual
hospital stay was defined as the first documented inpatient sCr, as recommended by [7],
and then as a sliding baseline. All such diagnoses were made within a single hospital
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Table 1. Abbreviations and Notation
Abbreviation Description
AKI Acute kidney injury
ALR1 Anscombe LR1
AUC Area under the curve
CKD Chronic kidney disease
CLR Clinical LR
CV Cross validation
Dx Diagnosis
EHR Electronic health record
ESRD End-stage renal disease
GBC Gradient boosting classifier
GFR Glomerular filtration rate
RGBC Recent GBC
RHPLR1 Randomized HPLR1
RLR1 Randomized LR1
HC Current hospitalization
HP Prior hospitalizations
HP Hyperparameter
HPLR1 Highly penalized LR1
LR1 Logistic regression with l1-norm penalty
LSTM Long short-term memory
MGBC Medication GBC
MLR1 Medication LR1
PPV Positive predictive value
PP Predicted probability
PP Mean PP
PO Observed probability
PO Mean PO
PR Precision recall
Px Procedure
ROC Receiver operating characteristic
sCr Serum creatinine
STD Standard deviation
UN Urea nitrogen
stay (e.g., a case in which the rise in sCr occurred over two rapidly successive hospital
stays was ignored). It is possible that some patients who did have AKI were neither
assigned a code nor had their sCr measured, and would thus be invisible with respect to
AKI diagnosis.
Preprocessing
Medication descriptions were stripped of dosage information and treated as categorical
variables. Abnormal lab flags were constructed by combining EHR-generated flags (an
automated indication of, e.g., hyperkalemia) with test name. For features such as
diagnoses and procedures, each admission contained a list. The hospitalization with the
highest number, D, of diagnoses was identified. Given any other hospitalization with a
list of D′ diagnoses, D −D′ “non-diagnoses,” the number of diagnoses not assigned
relative to its peers, were added. This was done to enhance predictive performance, as
missingness patterns were useful for the related task of phenotyping [37]. Top-level
binary representation [38] was used for the hierarchical ICD-9, CPT-4, and DRG codes
and “code precision” is defined as the level at which the tree was accessed. For example,
for chronic kidney disease (CKD), precision 3 produces a single feature, 581, that
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contains any occurrence of 585.1-6 (CKD, Stages 1-6) or 585.9 (CKD, unspecified),
essentially grouping these codes. Alternatively, precision 4 ungroups the subcodes,
producing 7 different features, one for each administrative classification of CKD. An
exploratory grid search for precision of ICD-9, CPT-4, and DRG codes was performed
and discrimination found to be relatively insensitive, so code precision was fixed at 3, a
level at which different subgroups of AKI and CKD were aggregated.
All extremely sparse features (with fewer than 100 non-zero or non-missing elements)
were removed. Hence, for continuous values, features that were unobserved frequently or
frequently zero (continuous lab and demographic values in this dataset should generally
be nonzero) were removed; categorical variables that were rarely observed were removed.
Besides reducing training time, removing rarely-present features, which can be difficult
to gather, improves clinical applicability. This step did not need to be incorporated into
the pipeline as it was a form of response-independent dimensionality reduction.
Feature Extraction
Over time, all patients have some continuous risk, P (AKI). Using data from all
previous hospitalizations, HP , we hope to estimate the probability of AKI during the
current hospitalization, HC , at the time of hospital re-entry, P(AKIHC |HP ). An
example case illustrating the feature extraction procedure used throughout this study is
diagrammed in Fig 1. It was designed to compress longitudinal, irregular and
misaligned observations into a fixed-length representation. Summary statistics are used
for repeated measures since they are interpretable and shown by [39] to be effective for
some risk prediction problems. Note that a patient with n hospitalizations generates
n− 1 training samples.
EHR data is an irregularly sampled (e.g., sCr is not measured at an hourly
frequency), misaligned (e.g., sCr and hemoglobin are not consistently simultaneously
sampled) window into a patient’s renal health. The jth hospitalization can be
conceptualized as a matrix Hj where each row is one of N + 1 features and each
column corresponds to some time step ≤ τj + 1, the end time of hospitalization j. Since
observations are irregularly sampled and misaligned, it is convenient to transform the
time-indexed hospitalization matrix into a collection of N + 1 sequences s(H), where s
is a function that converts a time series to a sequence. The sequence s(hi,j) corresponds
to feature j of hospitalization i and has its own number of entries, τi,j + 1,
corresponding to the number of times feature i was recorded during hospitalization j.
Such sequences are useful because they can be summarized or transformed via some
function F without explicit imputation, albeit with information loss.
Summary functions can encode relevant characteristics of the generative process; e.g.,
a sum provides a sense of the number of tests along with some information about the
results of the tests. A higher number of sCr tests may reflect a heightened concern for,
or closer monitoring of, AKI and its metabolic consequences. F takes as input a
sequence and outputs the minimum, maximum, mean, variance, and sum for continuous
variables and sum for categorical variables. F (s(Hi)) is now a Mx1 fixed-length
representation of the N + 1 sequences in the ith hospitalization, where we have
increased the dimension M > (N + 1) by concatenating any vector outputs of F.
Let H refer to all hospitalizations before the rehospitalization for which P (AKI) is
to be estimated (e.g., the third in Fig 1). As with the sequences of laboratory
measurements, F (s(H)) is represented as a matrix whose entries are indexed by time of
admission. However, although the observations are now aligned, they are still irregularly
sampled. F (s(H)) can then again be converted to a sequence s(F (s(H))). Finally, the
sequence of hospitalizations s(F (s(H))) can be summarized, or aggregated, using G to
yield G(s(F (s(H)))), a P -dimensional vector, where any vector outputs of G have been
concatenated as with the hospitalization representations, so P > M . The full set of
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Fig 1. Feature extraction pipeline for estimating P (AKI) during
rehospitalization. We sought to estimate the probability of AKI during
rehospitalization given all of a patient’s previous hospitalizations, P(AKIHC |HP ), shown
by the red arrow. An example of three hospitalizations (H1, H2, H3) is shown. Here H1
and H2 are used to estimate P (AKI) during H3. The EHR captures raw data (shown
in boxes closest to the time series tracings) of which our dataset contains N + 1 features.
At each level, data is aggregated via domain-expertise-informed functions F and G. The
pipeline produces a single, fixed-length representation of all previous hospitalizations to
serve as input to a learning algorithm. Measurements from each hospitalization, and
series of hospitalizations, are treated as sequences, denoted with operator s.
hospitalization-level aggregation functions for G is: Administrative: Max (age), First
(race), Last (marital status, gender, insurance), Sum (DRG, discharge disposition,
length of stay, locations visited, diagnoses, CPT4/ICD9 procedure); Medications: Sum
(administration of medication by description, class, and subclass); Labs: Minimum,
Mean, Maximum, Sum, and Variance (labs and abnormal lab flags). By aggregating
over hospitalizations with G, most (not those that were “first” or “last”) categorical
variables are rendered continuous, so standard rather than minimum-maximum scaling
is used where necessary for regression.
There are benefits and drawbacks of this aggregation-based approach for time series
data. Benefits include easy determination of features since F and G (chosen by the
analyst) are known. The sum of sCr from prior hospitalizations is easy to understand; a
more complicated function learned from the data in a time-dependent algorithm might
not be so. A mirroring limitation is that F and G, invented by humans, are probably
not optimal for the task at hand (e.g., the optimal hospital aggregator is probably a
function with some weight decay over time, allowing distant events to be “forgotten”).
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Another drawback is loss of information on time between events (e.g., very frequent
testing might be informative) or recency of events (e.g., a very distant nephrotoxic
medication might be less important than a very recent one). We therefore implemented
a recurrent neural network as well, but this work would likely benefit from further
exploration of clinical time series methods, an active area of research [37,40–42].
Training
The algorithms used have hyperparameters (HP) (e.g., the number of estimators in
GBC or scale of the Laplace distribution in LR1) that must be set in addition to the
parameters. For learning algorithms with HP, “nested” cross-validation (CV) is
recommended [43,44] to provide an un-optimistic performance estimate. Pure nested
CV requires that both choosing the HP search space and conducting the HP search be
executed independently and identically within every fold. This is computationally
expensive because it allows for high complexity HP (e.g., GBC with a large number of
estimators or LR1 with a very small penalty) that lead to overfitting and slow training.
HP were therefore fixed at values found in preliminary experiments (manually or with
grid or random search [45]) to not overfit the data (as determined by a validation set
distinct from the test set) and to produce reasonable features per domain expertise. It
was also confirmed that performance on the test set of the fold used to determine HP
did not differ substantially from performance on the test sets of the other four folds.
In greater detail, our HP selection method was as follows: create splits for 5-fold CV.
Hence, we have folds 1-5, which consist of Train1, Train2, ..., Train5, and Test1, Test2,
..., Test5. To set HP, take Train1 and split it into a (sub)train set Train1Train and
validation set Train1Val. Fit different HP on Train1Train and see which HP makes
performance (per) for system (sys) per(sysHP (Train1Train)) ≈ per(sysHP (Train1Val)).
Note that we do not try a large number of different HP and select the one with best
performance on the validation set; we select the HP for which training and validation
errors are most similar. Also, we examine importances/coefficients from
sysHP (Train1Train) to ensure that they are reasonably related to renal function. If not,
increase regularization. With this process, choose HP , which were found by analyzing
Train1, so call them HPTrain1. Fix HPTrain1. Evaluate sysHPTrain1(Train1) on
Test1, where Train1Train+Train1Val = Train1. This is a pure estimate of generalization
performance. Now, keeping HPTrain1 fixed, evaluate sysHPTrain1(Train2) on Test2,
evaluate sysHPTrain1(Train3) on Test3, and so on. Note that there is necessarily overlap
between Train1 and Test2, ..., Test5. Hence, there is potential leakage from HPTrain1
into the performance estimates of Test2, ..., Test5 (but again not into Test1). During
training, we therefore checked that performance on Test1 was roughly similar to
performance on Test2, ..., Test5.
We name this process “pseudo”-nested CV because HP selection was not performed
independently in each fold as is required for pure nested CV. In pure nested CV, we
would have specified a search region for HP and allowed HP to be selected in every fold,
selecting HPTrain1 to be tested on Test1, HPTrain2 to be tested on Test2, and so on.
Knowing that choosing our HP manually using the data put us in danger of overfitting,
we purposely tried to choose HPTrain1 that would yield systems with lower capacity.
Also, note that manual choice of HP precludes comparison of algorithms because HP
choice is a confounder; our comparison is therefore over trained systems, not training
algorithms.
Fixed HP for GBC included maximum depth = 2, minimum samples per split = 150,
and minimum samples per leaf = 100 and for LR1 C = 2 x 10−3. To produce a
parsimonious, highly penalized LR1 (HPLR1), C was decreased to 2 x 10−4 (aiming for
≈ 12 features). For LR1, classes were weighted according to prevalence. Between GBC
and LR1, choice of learning algorithm was also an HP, but was wrapped into the inner
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folds of the nested CV as a grid search. In preliminary experiments, LR1, Ridge [46],
random forest [47], multilayer perceptron [48], and GBC were explored manually.
Ultimately, LR1 and GBC were chosen as candidates for the search since LR1 was close
enough to ridge (the problem was expected to be sparse) and GBC close enough to
random forest. As recommended in [49], log loss, rather than a binary metric, was
optimized in the searches.
Although a search was performed over learning algorithms, there was no intention of
comparing them outright (there are many confounders, e.g., HP choice). Rather, they
were intended for use in concert since both have benefits and drawbacks. A major
difference is that LR1 is linear in its parameters and therefore quite interpretable while
GBC is nonlinear and sometimes gives better off-the-shelf predictions (LR1 could be
enhanced with basis functions to rival, but this was not done here). Besides manual
setting of HP, all other steps were performed in a pipeline within each fold. Pipelines
were constructed to successively impute (using the most frequent value), scale (using
standard scaling; only for LR1), fit, and calibrate (using Platt’s scaling [50]). Training
data were split such that, in each fold, 75% of the observations were used to fit and
select classifiers, and the remaining 25% were held out and used to calibrate the
estimator with the lowest log loss. For HPLR1, there was no search over GBC.
In an additional experiment, we implemented a variance stabilizing Anscombe
transform for LR1 (ALR1) for the count and categorical variables. GBC seemed to be
unaffected by this transform because it is a tree-based system invariant to monotone
transformations of the input. Since l1-norm penalty is known to select one and discard
x− 1 of x highly correlated features, for the purposes of reporting features, Both LR1
and HPLR1 were rerun with stability selection [51] (these were named RLR1 and
RHPLR1, respectively), which is less likely to discard the remaining x− 1 features. In
this case, the penalty weight, C2, on the final classifier was roughly nonexistent (vanilla
logistic regression) because the feature selection step with penalty weight C1 regularized.
RLR1 randomized selection had C1 = 0.5 and C2 = 1; RHPLR1 had C1 = 0.2 and
C2 = 1. For both RLR1 and RHPLR1, the stability selection sampling fraction was 0.75
with 50 resamples.
To explore alternative strategies for repeated measures, the first-described
experiment was redone exactly, but repeated samples were weighted such that each
patient received equal total representation (e.g., a patient with 3 samples was weighted
by 1/3; a patient with 2 by 1/2), producing weighted GBC (WGBC), weighted LR1
(WLR1), and weighted HPLR1 (WHPLR1); alternatively, one sample per patient was
randomly selected to produce independent data, producing sampled GBC (SGBC),
sampled LR1 (SLR1), and sampled HPLR1 (SHPLR1). Also, for repeated measures, we
implemented a recurrent neural network with long short-term memory (LSTM) cells [34]
that processed the two most recent hospitalizations in sequence. This recurrent system
obviated the need for the hospital aggregator G. We set the number of hidden layers and
units a priori and searched over levels of dropout. Thus in contrast to GBC and LR, we
did not set HP for LSTM by using features in one fold of cross validation, and therefore
the LSTM was trained with pure nested cross validation. For insertion of LSTM into a
pipeline, the Scikit-learn scaler and imputer were decorated to process tensors.
To explore the effect of previous hospitalizations, the first-described experiment was
redone exactly, but using only the most recent hospitalization as input (results are
reported for “recent” GBC: RGBC). The original decision to include data from all
previous hospitalizations was based on the premise that it is better to provide more
rather than less information to a learning algorithm (although this requires an extra
step of aggregation over hospitalizations). As medications are potentially modifiable risk
factors, GBC and LR1 were also refit exactly as in the first-described experiment, but
with only medications as features (MGBC and MLR1). We also implemented a system,
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CGBC, with only a handful of clinically known risk factors from [52]: age, underlying
renal insufficiency (prior AKI or CKD), diabetes, and heart failure. Logistic regression
was used by setting C=1000 with ridge regression (in order to remain in the scikit-learn
ecosystem where all logistic regressions are penalized). We also randomly permuted the
response variable and refit exactly as in the first-described experiment to produce noise
GBC (NGBC).
Assumptions
It is assumed that the majority of patients in the dataset who have an episode of AKI
are, by medical history, high risk for AKI. Conversely, we assume that the majority of
patients without AKI have past medical histories that are low risk for AKI. This is
paradoxically a strong assumption. To see why, consider a patient with high risk for
AKI. We hope to associate this patient’s prior hospitalizations with high risk. Upon
rehospitalization, however, suppose that an admitting provider, evaluating the risk as
high, decides to administer extra fluids. Ultimately, and fortunately for the patient, this
effort may prevent AKI. However, the training set now contains a high risk history
coupled to a hospitalization in which AKI did not occur. Hence, this patient’s high-risk
history will incorrectly be associated with a flipped label of non-AKI. Conversely, a
patient with low AKI risk might receive a medication with the potential for causing
AKI, resulting in a similar mismatch. It is therefore assumed that the modifications of
disease course just described contribute negligible bias to our predictions, but
recognized that this bias is not detectable via internal or external validation. If this
assumption is false, it would invalidate our approach, and future work will focus on
developing methods to test this assumption. Notably, this assumption has been shown
to fail in a previous study on pneumonia where patients with risk-increasing asthma
were given systematic, preferential treatment, effectively flipping their labels [53]. Bias
resulting from interventions could be removed by incorporating events that occur during
rehospitalization as predictors. However, this is precluded because an intervention could
occur all the way up to AKI (e.g., a provider might discontinue intravenous fluids and
increase the risk of AKI). Many of our labels are diagnosis codes assigned at the end of
the hospitalization, so we do not know when AKI occurred. With the interpretable
HPLR1, it is at least possible to confirm that the features are reasonable and appear
not to be subject to this bias.
It is also assumed that a time-based (2-year) sample approximates an ideal
patient-based sample. Repeating training on a patient-based sample would be a useful
complement to this study, and if implemented in the EHR should be formulated as such,
since a patient may have a previous hospitalization or rehospitalization outside of the
sample. Similarly, it is assumed that our dataset sampled from only one hospital
network is representative enough for learning local patterns. We strongly recommend
retraining if the model is to be used outside of the population that generated the
training data. Finally, it is assumed that undetected AKI from lack of sCr
measuremenst or no assignment of a diagnosis code is a rare event.
Evaluation
For evaluation, 50 iterations of nested (except HP determination, as described above)
5-fold CV were performed. Since any two hospitalizations from the same patient were
correlated, CV sampling was “grouped” at the patient level. Micro (over all 250 outer
folds) and macro (over 50 iterations) mean and standard deviation of all metrics are
reported. As recommended in [49], a probability estimate rather than binary output is
provided so the final decision can be made with maximal information at the point of
care (e.g., if one patient has 0.499 risk and another has 0.501, these should not be
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converted to 0 and 1 by an algorithm, but by a provider in clinical context). Although
calibration is primarily assessed, discrimination is also described, as is standard practice,
with receiver operating characteristic (ROC) and precision-recall (PR) curves and
corresponding areas. For calibration, curves are shown with Brier score. Every
calibration curve shown contains 10 bins. In addition to hospitalization-level
performance of GBC, patient-level performance is also analyzed. This is conveyed via
scatter plots of the average risk per patient (e.g., a patient with two hospitalizations,
one of which had AKI and the other of which did not has 0.5 observed risk) by the
average predicted risk. Calibration curves are superimposed for the cases that had 0 or
1 observed risk (all of the hospitalizations and a subset of the patients).
Since algorithms have potential to harm certain subgroups, algorithmic fairness is an
active area of research [54,55]. Here, an error analysis is performed with special focus
on the black box GBC, to detect subgroups for which this might be the case. After
stratifying by outcome, the same iterated, semi-nested CV procedure described above
was used to fit an l1-penalized linear regression with either diagnosis, race, gender, or
age alone as features and the absolute magnitude of the error as the response (minimum
0, maximum 1). To analyze error by utilization, patients were binned based on the
number of hospitalizations that they generated and average error was plotted for each
bin. The relationship between number of hospitalizations from a patient and that
patient’s impact on coefficients was assessed by removing all hospitalizations from each
patient and fitting HPLR1 and then comparing to the coefficients of HPLR1 fit on the
full dataset. The comparison was made using l1 norm because the coefficient vectors
were low dimensional for HPLR1. Error was also assessed as it related to method of
diagnosis (code or sCr) and variance of predicted risk.
Computing environment
All computational work was performed in Python 2.7.14. Libraries in scikit-learn [56]
and the SciPy ecosystem [57–62] were used throughout. Code was run on a linux-based
cluster. Each experiment was run via an sbatch script requesting roughly 1 node and
100 to 200 GB of random-access memory. All iterations were distributed using job
arrays. Code will be made available upon publication on github.com.
Results
AKI Cohort Selection
A cohort selection schema and results are shown in Fig 2 along with a histogram of the
number of hospitalizations per patient. During the two-year window, 146,800 patients
generated 261,319 hospitalizations; after excluding hospitalizations with age at
admission < 18, 107,036 patients generated 199,545 hospitalizations. Excluding
hospitalizations preceded by diagnosis of ESRD, but not preceded by a renal transplant,
yielded 197,046 hospitalizations for 107,033 patients. Of these patients, 34,505 (32.2%)
were rehospitalized at least once during the two-year period, accounting for 123,828
(62.8%) of total hospitalizations. Within hospitalizations generated by these patients,
90,013 were rehospitalizations (i.e., not the first hospitalization from that patient in our
dataset). There were 5,618 (6.2%) cases of AKI. The hospitalization:patient ratio was
1.4 for the cases, and 2.5 for controls. Hence the cases showed more patient-level
diversity than the controls, which were generated by patients who returned more often.
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Fig 2. Cohort selection. On the top left, the selection procedure used to obtain the
rehospitalization cohort is shown. On the top right, the distribution of the 197,046
hospitalizations not preceded by a diagnosis of ESRD is shown. On the bottom, a
schematic of predictor/target generation is shown for an example patient with n
hospitalizations from which n− 1 training cases were derived. For each target
rehospitalization, y, data from all prior hospitalizations, X, are used as predictors.
Multiple prior hospitalizations were aggregated using G as described above.
AKI Diagnosis
AKI was identified by both diagnosis code and sCr, shown in Table 2. Of all 197,046
hospitalizations in our cohort (not by a patient with previous diagnosed ESRD), 11,166
(5.7%) involved AKI; 4,135 were diagnosed by sCr but not code, 2,747 by sCr and code,
and 4,284 by code but not sCr.
Table 2. AKI diagnosis distribution
Lab Diagnosis Total
+ -
Coding Diagnosis + 2,747 4,284 7,031
- 4,135 185,880 190,015
Total 6,882 190,164 197,046
Cohort demographics for all 124,518 adult hospitalizations (after exclusion of cases
following a diagnosis of ESRD) generated by patients who were rehospitalized at some
time are shown in Table 3. This corresponds to the fourth cohort shown in Fig 2. These
summary statistics are by hospitalization, and not patient, and therefore some patients
are represented multiple times. Note that ESRD is present since a hospitalization can
contain a diagnosis of ESRD (i.e., permanent kidney failure) even though it does not
follow a hospitalization with diagnosis of ESRD. General cohort demographics
corresponded to known findings. As expected, hospitalizations in which AKI occurred
had higher age on admission [25] and longer duration [3]. A higher proportion of AKI+
subjects were male and white. Also more prevalent in the AKI+ hospitalizations were
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previously identified risk factors [4, 14,63] including prior CKD diagnosis [64], prior
dialysis procedures without ESRD [64], congestive heart failure [63,65], diabetes [63],
shock [52], and liver failure [66,67].
Table 3. Cohort demographics Statistics are computed per hospitalization. There
are a total of 124,518 hospitalizations from 34,505 patients, each with more than one
hospitalization. These are therefore all hospitalizations generated by patients in the final
cohort (including the first hospitalization from each patient, for which AKI is not
predicted).
AKI+ (n=7,762) AKI- (n=116,756)
Mean ± STD Median Mean ± STD Median
Age 62.06 ± 17.23 63.00 44.01 ± 18.86 42.00
Length of Stay 14.22 ± 22.59 7.89 1.89 ± 4.89 0.33
Count % Count %
Female 3,497 44.0 67,811 56.0
American Indian 5 0.0 205 0.0
Asian 61 1.0 1,364 1.0
Black 1,822 23.0 39,038 28.0
White 5,557 73.0 68,003 64.0
Other 322 4.0 8351 7.0
Chronic Kidney Disease (CKD) 2,574 37.0 2,349 2.0
ESRD 246 10.0 213 1.0
Dialysis 538 15.0 217 1.0
Renal Transplant 22 0.0 29 0.0
Unspecified Renal Failure 238 3.0 72 0.0
Congestive Heart Failure 2,227 29.0 3,218 2.0
Diabetes 2,651 34.0 9,031 7.0
Shock 997 14.0 2,700 2.0
Liver Failure 720 9.0 1,076 1.0
Rhabdomyolysis 189 2.0 225 0.0
Evaluation
The final dataset had 5,308 features at a code precision of 3 digits. After removing
features that were observed in fewer than 100 of the samples, 3,387 (63.8 %) remained.
HP are detailed in Supplement S1 File. All performance metrics are reported in Table 4;
since the distributions of these individual metrics were approximately normal
(Supplement S2 Fig), standard deviation is reported. Also because of approximate
normality, the Bayesian correlated t-test [68] was used to compare systems (Table 5).
We specified a priori the regions of practical equivalence (ROPE) for ROC AUC, Brier
Score, and PR AUC as, respectively, (0.01, 0.001, 0.01). For metric m with ROPE r
and systems in row i and column j, tuples in the table correspond to
(P (m(i)−m(j)) > 0.5r, P (m(i)−m(j)) ∈ r, P (m(i)−m(j)) < −0.5r or, informally,
(P(i higher score than j), P(i and j practically equivalent), P(j higher score than i)).
Note that ROC and PR are both ideal if 1 and Brier score is ideal if 0, so the Brier
table is opposite the other two. We again emphasize that this is a comparison of trained
systems, not of the training algorithms, because HP is a confounder. GBC curves are
displayed in Figure 3. In the low range, GBC has transposed-sigmoidal tendency
suggesting overconfidence (predicting low probabilities as too low and high probabilities
as too high). This may be due to dependencies or perhaps a relatively small ratio of
cases to features. In contrast to high ROC AUC, precision suffers greatly when the
threshold is lowered. PPV is dependent on the prevalence of AKI; even a small false
positive rate (FPR) might lead to a high false positive (FP) count if the controls
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outnumber the cases, as is the case with AKI. Thus even with a low FPR, it can be
expected that detecting a TP would cost many FP. FP in AKI, relative to other
diseases, are most often fairly innocuous. Preventative measures consist mainly of
hydration and medication review. In some cases, however, a FP might result in
withholding necessary treatment (e.g., imaging or medication) or unnecessary
Nephrology consults [69]. This shortcoming is therefore notable. Ultimately, however,
we recommend that a decision based on some threshold never be provided to a user in
place of a probability estimate [49].
Fig 3. GBC evaluation. ROC, Calibration, and PR curves for 50 iterations of 5-fold
CV (250 lines shown; each of 50 iterations has 5 lines corresponding to the 5 outer folds
of CV). The black diagonal line represents chance for the ROC curve and ideal for the
calibration curve. Results are reported per hospitalization, not patient. Alpha level=0.5,
line weight=0.5.
The distributions of errors by method of diagnosis (i.e., by code or sCr) are shown in
Supplement S3 Fig. Without rigorous analysis, it appears that, expectedly, cases
detected by both methods have lower mean error than cases detected by one or the other.
Notably, cases detected by sCr but not administrative code appear to have higher errors
than cases detected by both or cases detected by code but not sCr; this is also to be
expected since many cases detected by sCr but not code were likely subtle AKI episodes,
or perhaps even correspond to variation in sCr for reasons impossible to discern from
the data, but not due to AKI. Gross visual differences between the distributions are not
noted, but the slight differences could be an interesting future investigation.
Performance curves for LR1, ALR1, and RLR1 are shown in Supplement S4 Fig,
Supplement S5 Fig, and Supplement S6 Fig. Performance curves for HPLR1 and
RHPLR1 are shown in Supplement S7 Fig and Supplement S8 Fig. Stability selection
included more variables, perhaps since it was less influenced by colinearity. The
performance difference between full LR1 and reduced HPLR1 suggests that adjusting
for more variables improves, but also increase the variance, of the calibration curves.
Performance curves for weighted WGBC are shown in Supplement S9 Fig. When
weighting, averaged calibration curves appear to be slightly closer to identity
(Supplement S10 Fig). When weighting, performance by utilization, shown in
Supplement S11 Fig, appears unchanged. Performance curves for WLR1 and WHPLR1
are shown in Supplement S12 Fig and Supplement S13 Fig, respectively. Performance
curves for sampled SGBC, SLR1, and SHPLR1 are shown in Supplement S14 Fig,
Supplement S15 Fig, and Supplement S16 Fig. Sampling leads to reduced sample size,
and therefore performance appears to generally be worse, but the change is not drastic.
Notably, however, PR AUC increases. Performance curves for RGBC, which takes into
account only the most recent hospitalization, are shown in Supplement S17 Fig. It is
evident that most predictive power is contained in the most recent hospitalization, but a
small gain is achieved by including more distant hospitalizations (GBC appears slightly
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Table 4. Predictive performance. ROC = Receiver Operating Characteristic, PR =
Precision Recall, ALR1 = Anscombe LR1, GBC = Gradient Boosting Classifier, LR1 =
l1-Penalized Logistic Regression, LSTM = Long Short-term Memory, HP = Highly Penalized,
W = Weighted, S = Sampled, R = Recent (for GBC) or Randomized (for LR1, HPLR1), M =
Medication, N = Noise.
ROC AUC Brier Score PR
GBC Micro: 0.86737 ± 0.00566 0.04901 ± 0.00179 0.32568 ± 0.01502
Macro: 0.86737 ± 0.00045 0.04901 ± 8e-05 0.32568 ± 0.0026
LR1 Micro: 0.86012 ± 0.00602 0.05038 ± 0.00187 0.30068 ± 0.01533
Macro: 0.86012 ± 0.00041 0.05038 ± 0.00011 0.30068 ± 0.00182
ALR1 Micro: 0.86188 ± 0.00606 0.05019 ± 0.00187 0.30445 ± 0.01571
Macro: 0.86188 ± 0.00113 0.05019 ± 0.00025 0.30445 ± 0.00411
RLR1 Micro: 0.85312 ± 0.00621 0.05068 ± 0.0019 0.30227 ± 0.01453
Macro: 0.85312 ± 0.00055 0.05068 ± 9e-05 0.30227 ± 0.00159
HPLR1 Micro: 0.84545 ± 0.0064 0.05158 ± 0.00191 0.29002 ± 0.01361
Macro: 0.84545 ± 0.00037 0.05158 ± 5e-05 0.29002 ± 0.00091
RHPLR1 Micro: 0.848 ± 0.00651 0.05102 ± 0.00192 0.29869 ± 0.0142
Macro: 0.848 ± 0.05102 0.05102 ± 8e-05 0.29869 ± 0.00122
WGBC Micro: 0.86328 ± 0.00568 0.04932 ± 0.00178 0.31572 ± 0.01541
Macro: 0.86328 ± 0.00059 0.04932 ± 0.0001 0.31572 ± 0.00261
WLR1 Micro: 0.84965 ± 0.00606 0.0507 ± 0.00188 0.29564 ± 0.01425
Macro: 0.84965 ± 0.00046 0.0507 ± 6e-05 0.29564 ± 0.00091
WHPLR1 Micro: 0.77923 ± 0.01208 0.05387 ± 0.00209 0.25742 ± 0.01609
Macro: 0.77923 ± 0.00308 0.05387 ± 0.00013 0.25742 ± 0.00385
SGBC Micro: 0.85962 ± 0.00744 0.05326 ± 0.00195 0.33161 ± 0.02153
Macro: 0.85962 ± 0.00226 0.05326 ± 0.00045 0.33161 ± 0.00631
SLR1 Micro: 0.84752 ± 0.00792 0.05486 ± 0.00206 0.30596 ± 0.02022
Macro: 0.84752 ± 0.00214 0.05486 ± 0.00049 0.30596 ± 0.00548
SHPLR1 Micro: 0.7706 ± 0.01157 0.05754 ± 0.00229 0.28547 ± 0.01992
Macro: 0.7706 ± 0.00366 0.05754 ± 0.0005 0.28547 ± 0.0054
RGBC Micro: 0.86306 ± 0.00572 0.04927 ± 0.00178 0.32198 ± 0.01526
Macro: 0.86306 ± 0.00039 0.04927 ± 6e-05 0.32198 ± 0.00185
MGBC Micro: 0.82635 ± 0.00693 0.05161 ± 0.00189 0.27079 ± 0.01484
Macro: 0.82635 ± 0.00075 0.05161 ± 8e-05 0.27079 ± 0.00172
MLR1 Micro: 0.80671 ± 0.00764 0.0564 ± 0.0022 0.22051 ± 0.01397
Macro: 0.80671 ± 0.00137 0.0564 ± 0.00019 0.22051 ± 0.00212
LSTM Micro: 0.85744 ± 0.00592 0.05027 ± 0.0018 0.28209 ± 0.01547
Macro: 0.85744 ± 0.0008 0.05027 ± 0.00012 0.28209 ± 0.00526
CLR Micro: 0.80149 ± 0.00785 0.05356 ± 0.00204 0.22926 ± 0.01467
Macro: 0.80149 ± 0.00034 0.05356 ± 6e-05 0.22926 ± 0.0009
NGBC Micro: 0.49938 ± 0.00837 0.05853 ± 0.0015 0.06251 ± 0.00242
Macro: 0.49938 ± 0.00399 0.05853 ± 2e-05 0.06251 ± 0.00094
better than RGBC, but the difference is in the region of practical equivalence). Notably,
in GBC there are virtually no sums over hospitalizations, only means; when G
aggregates sequences of hospitalizations of variable length, sums have much higher
variance (perhaps why GBC vastly favors labs, which can be converted to less volatile
means, while diagnoses are mostly counts). However perhaps when G is the identity,
such as with RGBC (features not shown), counts are just as well as means. The
medication-based performance curves for MGBC and MLR1 are shown respectively in
Supplement S18 Fig and Supplement S19 Fig. Performance of CLR is shown in
Supplement S20 Fig. This system depends mostly on codes rather than continuous
values, probably explaining its reduced performance. Performance of LSTM is shown in
Supplement S21 Fig. This system was not exhaustively optimized, so performance is not
as strong, but it has the obvious benefit of requiring less feature engineering. Results for
NGBC performance, a utilization analysis, and the STD with respect to error are shown
in, respectively, Supplement S22 Fig, Supplement S23 Fig, and Supplement S24 Fig.
NGBC just predicted 0.06 for every sample.
Fig 4 shows the distributions of the probability estimates per hospitalization
alongside the same per patient, where the risk is averaged over hospitalizations.
Although GBC was not optimized for patient-level prediction, aggregate calibration
(averaged over CV folds and trials) appears to be good at the patient level. The
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Table 5. Predictive performance comparison. ROC = Receiver Operating
Characteristic, PR = Precision Recall, ALR1 = Anscombe LR1, GBC = Gradient Boosting
Classifier, LR1 = l1-Penalized Logistic Regression, LSTM = Long Short-term Memory, HP =
Highly Penalized, W = Weighted, S = Sampled, R = Recent (for GBC) or Randomized (for
LR1, HPLR1), M = Medication, N = Noise.
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calibration curve consisting of averaged predictions is much better than the individual
calibration curves per fold. This may be related to the difficulty in sampling each fold
at the patient level when there is such a wide variety of hospitalizations per patient.
More could be done on characterizing the distributions of the calibration curves. It is
apparent from these plots that it is more difficult to predict cases than controls; the
distributions of predictions for cases are quite broad and appear almost bimodal.
Fig 4. GBC hospitalization- and patient-specific risk distributions. Observed
hospitalization-level risk is plotted against predicted risk (top row) and patient-level
mean observed risk against mean predicted risk (bottom row). Distributions of
predictions PP are shown at the hospitalization and patient level. At patient level,
distributions that are difficult to discern from the scatter plot are shown. In the scatter
plots, alpha level is 0.05 and the red calibration curve corresponds to all hospitalizations
or to patients who had either mean risk over hospitalizations of 1 or 0. The calibration
curves are computed according to the macro-averaged predicted output per
hospitalization or patient over the 50 iterations of 5 fold CV (over 250 total folds). Ideal
calibration is the dotted black diagonal. Histograms have 1000 bins to give necessary
resolution. PO = observed risk per hospitalization, PP = predicted risk per
hospitalization, PO = mean observed risk over hospitalizations, PP = mean predicted
risk over hospitalizations.
Uncertainty of predictions appears to increase with increasing predicted risk, even
when stratifying by outcome, as shown in Fig 5. Although the range is fairly small
(0-0.10), the distributions in Fig 4 show that many of the high risk cases have low
predicted risk, so the uncertainty is meaningful. We highlight the necessity of (at least
empirical) prediction intervals for GBC, if ever considered for deployment.
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Fig 5. GBC prediction variance. The mean and standard deviation of predicted
probabilities are plotted over iterations (per hospitalization). Alpha=0.01 for all plots.
Error analysis of GBC
We sought to identify specific subgroups which are easily recognized by a provider and
for which the best performing GBC might make errors. To show that the linear
regressions used for this purpose were well fit, train, validation, and test MSE from the
fold used to set HP is provided in Supplement S25 Table. HP are provided as well,
chosen manually as in the main study by making the train-validation difference in a
single fold small, although usually a penalty was not necessary. The mean and standard
deviations of nonzero coefficients are shown in Table 6. The diagnoses associated with
increased error in the cases (failure to predict AKI when it occurred) are assigned to
patients who were hospitalized for reasons not directly related to the kidney (substance
abuse). Conversely, the diagnoses associated with small errors are obviously associated
with AKI (e.g., we see especially accurate predictions of high AKI risk in
hospitalizations preceded by frequent AKI or CKD). The diagnoses associated with
increased error in the controls (failure to rule out AKI when it did not occur) were,
expectedly, AKI, CKD, and anemia. This is not as revelatory as the cases; GBC has
learned that prior kidney disease is associated with future kidney disease, which is a
well known phenomenon. These may correspond to cases in which interventions
occurred for high risk patients (the label flipping mentioned in Assumption (1)).
There were no detected relationships to the error (all coefficients were 0) for different
races (American Indian, Asian, Black, Black/American Indian, Declined, Other,
Unknown, and White). This is very comforting, although it is difficult to make a
general conclusion for the rare races (see Fig 3 for frequencies). Gender also, favorably,
showed no relationship to error. As shown in Table 6, increasing age leads to lower error
in the cases and higher error in the controls. Hence errors occur because predicted risk
is sometimes too high in older patients when they are healthy and too low in younger
patients when they are not. Age is a particularly well-recorded variable; it is unclear
what variable could be adjusted for to remove this bias, but it is likely that explicit
stratification might be in order. In this large sample, the healthy young simply
overwhelm the high risk young and opposite for the older patients. A plot of error by
age is shown in Supplement S26 Fig to complement the findings in Table 6. It is likely
that, at least in part, the correlation of the errors with features indicates slight
underfitting; had higher capacity HP been permitted, these patterns might have been
detected (at the risk of overfitting in other ways). As described above, bias was
prioritized above variance in order to avoid overfitting, but now this error analysis gives
some insight into who might suffer from poor predictions as a result.
Error and STD of predicted probability against utilization is shown in Fig 6. The
average error for controls decreases with the utilization. For cases, the pattern is not
clear, but it also appears to decrease. Hence predictions are better for patients with
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Table 6. Coefficients of features associated with error. For diagnoses, features
correspond to the count assigned in prior hospitalizations. Note that age and diagnosis
were fit in separate regressions despite being displayed in the same table.
Cases (AKI +)
Lasso (+) Mean (95% CI)
“Non-present” Dx 0.0071 (0.0069, 0.0073)
Non-dependent abuse of drugs 0.0030 (0.0028, 0.0032)
Lasso (-) Mean (95% CI)
AKI -0.0476 (-0.0479, -0.0473)
CKD -0.0301 (-0.0304, -0.0297)
Other and unspecified anemias -0.0066 (-0.0068, -0.0063)
Convalescence and palliative care -0.0039 (-0.0042, -0.0036)
Hypertensive chronic kidney disease -0.0006 (-0.0008, -0.0004)
Heart failure -0.0003 (-0.0003, -0.0002)
Cardiac dysrhythmias -0.0001 (-0.0002, -0.0001)
Age -0.0271 (-0.0272, -0.0269)
Controls (AKI -)
Lasso (+) Mean (95% CI)
AKI 0.0166 (0.0164, 0.0167)
CKD 0.0112 (0.0111, 0.0113)
Other and unspecified anemias 0.0014 (0.0014, 0.0015)
Age 0.0236 (0.0235, 0.0236)
many hospitalizations. STD however appears to increase with utilization for cases,
unlike for controls. Since this dataset is a time-window sample, high utilizers are
overrepresented (recall that a patient with multiple hospitalizations appears multiple
times in the dataset). This is common in medical prediction problems (e.g., [16] had a
final analysis cohort with roughly 1.6 million admissions generated by roughly 600,000
patients; a readmission study [70] had roughly 3.3 million admissions generated by 1.3
million patients). We hypothesize that high utilizers have strong influence over
parameters. Consider two patients without AKI; one is hospitalized 10 times and each
time merely visits the emergency department and another is hospitalized twice for heart
failure exacerbation. The patient with 10 hospitalizations generates 9 training examples
while the one with heart failure exacerbation generates only one. The former will have
much stronger influence over coefficients.
The impact of each patient on the coefficient vector of HPLR1 is shown in
Supplement S27 Fig. There are patients who are relatively high and relatively low
utilizers who have substantial impact on the coefficients. Since there are many low
utilizers, perhaps there is greater probability that there is a very different patient that
might influence coefficients more. However, extreme influencers seem to be relatively
high utilizers. Although this optimizes hospitalization-level performance (a prediction
error for the patient who generates 10 hospitalizations may lead to 10 errors, while an
error for the patient who generates 1 will only result in one, all else being equal) this
might not be fair. In WGBC, we have downweighted hospitalizations from high utilizers
such that the 9 training examples have a net effect on the coefficients equal to the 1
training example. Making patient influence over coefficients more equal optimizes
performance on the level of patients rather than hospitalizations, but we do not see a
clear change in the utilization analysis. Another option for future work might be mixed
effects approaches.
Features
Predictors specific to rehospitalized patients are described. Note that these should be
considered predictors, not risk factors, since causality is never established. Further,
many of the features are correlated, so it is important to note variance. It is possible
that some features in the ensuing tables might have correlated counterparts that could
just as well have been selected in their places. We still maintain that these tables are
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Fig 6. GBC error by utilization. The mean and STD absolute error is shown as a
function of the number of hospitalizations. Patients were binned based on the number
of hospitalizations in the dataset and then, over bins, the mean error and STD of the
predictions were computed. Stratification by outcome is performed since it was earlier
established that the hospitalization:patient ratio is higher in cases than in controls.
useful (1) to demonstrate that the systems depend on reasonable predictors and (2) to
report potential predictors for specification of a more parsimonious system that could
be validated on a different dataset. Both of these objectives can be met despite the
correlated nature of the features. Also, note that the relationships between these
features and AKI are associative, not necessarily causal. The distribution of feature
importances/coefficients was very skewed and we believe the interesting ones are
adequately contained in the top 40, but this cutoff is still arbitrary. With these caveats
in mind, we discuss some interesting findings. We reported 95% bootstrap [71]
confidence intervals (10,000 iterations using [72]) instead of standard deviation as we
had with the metrics because it was difficult to check each coefficient’s distribution for
symmetry. Importance scores were computed via scikit-learn according to the Gini
importance definition in [73].
GBC and LR1
The 40 features with the highest micro-averaged GBC importance scores and largest
absolute LR1 coefficients are shown in Table 7 and RLR1 coefficients are shown in
Supplement S28 Table. Some features were comprised of sub-features (e.g., diagnosis
codes contained many sub-diagnoses). For display in tables, these were succinctly
renamed via a representative term (e.g., diuretics or CKD), most frequent sub-features,
or general group names from [74].
For GBC, many features correspond to known indicators of acute or chronic kidney
dysfunction (e.g. diagnosis of AKI, sCr, UN, GFR). As our features are gleaned from
prior hospitalizations, they suggest that prior acute or chronic kidney disease increases
the probability of AKI. Age is associated with declining kidney function in general, as
well as a higher incidence of CKD and other conditions strongly associated with renal
disease. Thus it is not surprising that age is the strongest predictor of AKI in both
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Table 7. Feature importances/coefficients for GBC and LR1. For laboratory
results, the first function is G, aggregation over hospitalizations, and the second is F ,
aggregation within a hospitalization; e.g., “mean max sCr” is the mean over
hospitalizations of the maximum sCr of each hospitalization.
GBC Mean (95% CI)
Age 0.0409 (0.0404, 0.0414)
Mean count abnormally high urea nitrogen 0.0351 (0.0338, 0.0365)
Count “non-present” DRGs 0.0295 (0.0289, 0.0301)
Count Dx: AKI 0.0168 (0.0161, 0.0175)
Mean count abnormally low hemoglobin 0.0160 (0.0152, 0.0168)
Mean sum urea nitrogen 0.0153 (0.0144, 0.0162)
Mean sum sCr 0.0143 (0.0135, 0.0151)
Mean min direct bilirubin 0.0139 (0.013, 0.0149)
Mean max albumin 0.0128 (0.0117, 0.0139)
Count immunosuppressant medications 0.0124 (0.0116, 0.0132)
Max mean urea nitrogen 0.0118 (0.0109, 0.0127)
Mean count abnormally high sCr 0.0113 (0.0106, 0.012)
Count pharm subclass: Loop diuretics 0.0104 (0.0098, 0.011)
Count pharm subclass: K-sparing diuretics 0.0099 (0.0089, 0.0108)
Min min direct bilirubin 0.0098 (0.0088, 0.0107)
Mean count abnormal glomerular filtration rate-caucasian 0.0088 (0.0082, 0.0094)
Count “non-present” Dx 0.0084 (0.0078, 0.009)
Min mean chloride 0.0080 (0.0074, 0.0087)
Count “non-present” CPT4 Px 0.0078 (0.0072, 0.0084)
Max max sCr 0.0078 (0.0071, 0.0084)
Mean max urea nitrogen 0.0073 (0.0065, 0.008)
Mean mean hemoglobin 0.0071 (0.0065, 0.0077)
Count Px: injection of glucagon, haloperidol, heparin, enoxaparin 0.0070 (0.0065, 0.0076)
Spironolactone 0.0067 (0.0058, 0.0076)
Count discharges to Hospice/Medical Facility 0.0066 (0.0062, 0.0071)
Count Dx: artificial opening status (e.g., tracheostomy) 0.0065 (0.0058, 0.0072)
Min max albumin 0.0065 (0.0058, 0.0071)
Var count abnormally high urea nitrogen 0.0057 (0.0049, 0.0065)
Count allopurinol 0.0056 (0.0049, 0.0062)
Min min Glomerular filtration rate-Black 0.0055 (0.0049, 0.0061)
Count carbapenems 0.0055 (0.0048, 0.0062)
Spinal procedures w/o CC/MCC 0.0053 (0.0044, 0.0061)
Sum max glomerular filtration rate-Black 0.0052 (0.0047, 0.0057)
Max min sCr 0.0052 (0.0047, 0.0058)
Count Dx: Disorders of fluid electrolyte and acid-base balance 0.0052 (0.0047, 0.0057)
Mean sum glomerular filtration rate-Black 0.0052 (0.0045, 0.0059)
Count Dx: Diabetes Mellitus 0.0051 (0.0046, 0.0056)
Max max urea nitrogen 0.0051 (0.0045, 0.0058)
Max max hemoglobin 0.0049 (0.0043, 0.0055)
Sum max hemoglobin 0.0048 (0.0042, 0.0054)
LR1 (+) Mean (95% CI)
Age 0.5846 (0.5825, 0.5867)
Mean mean urea nitrogen 0.1127 (0.108, 0.1175)
Count Dx: AKI 0.0974 (0.0956, 0.0993)
Mean max glucose 0.0905 (0.0882, 0.0927)
Mean mean sCr 0.0587 (0.0532, 0.0641)
Gender: Male 0.0505 (0.0455, 0.0554)
Mean var glomerular filtration rate-Caucasian 0.0442 (0.0424, 0.046)
Max mean sCr 0.0386 (0.0337, 0.0433)
Count discharges with home health organization care services 0.0290 (0.0271, 0.0309)
Max mean urea nitrogen 0.0251 (0.0215, 0.0286)
Count Dx: Chronic pulmonary heart disease 0.0241 (0.0228, 0.0254)
Min min direct bilirubin 0.0241 (0.0221, 0.0261)
Mean min direct bilirubin 0.0227 (0.0208, 0.0245)
Count DRG: Hepatobiliary diagnostic procedures with MCC 0.0213 (0.0196, 0.0229)
Count Px: Pathology consult 0.0195 (0.0181, 0.021)
Count Px: Assay of blood lipoprotein or of magnesium 0.0186 (0.0161, 0.021)
Mean max urea nitrogen 0.0182 (0.015, 0.0213)
Count Px: Assay of urine sodium 0.0179 (0.0163, 0.0194)
Min min sCr 0.0173 (0.0144, 0.0201)
Last primary insurance: other 0.0171 (0.0158, 0.0185)
LR1 (-) Mean (95% CI)
Count “non-present” DRGs -0.2126 (-0.2294, -0.1964)
Mean min albumin -0.2122 (-0.2171, -0.2076)
Mean min albumin -0.0623 (-0.0671, -0.0575)
Gender: Female -0.0610 (-0.0659, -0.0561)
Count Location: High risk labor and delivery unit -0.0585 (-0.0613, -0.0558)
Count location: Emergency Department -0.0526 (-0.0606, -0.0443)
Min min glomerular filtration rate-Caucasian -0.0409 (-0.0446, -0.0373)
Mean min chloride -0.0393 (-0.0418, -0.0369)
Count Dx: Traumatic injuries -0.0331 (-0.036, -0.0301)
Mean mean albumin -0.0307 (-0.0347, -0.0263)
Count Admission on Tuesday -0.0288 (-0.033, -0.0246)
Count Admission on Saturday -0.0265 (-0.0307, -0.0221)
Count Dx: Injury from athletics -0.0252 (-0.0284, -0.0219)
Count discharges on Sunday -0.0202 (-0.0237, -0.0166)
Mean min glomerular filtration rate-Caucasian -0.0195 (-0.0229, -0.016)
Max min hemoglobin -0.0166 (-0.0202, -0.0128)
Min min albumin -0.0158 (-0.0187, -0.0129)
Max min bicarbonate -0.0109 (-0.0126, -0.0091)
Mean max albumin -0.0108 (-0.0128, -0.0088)
Mean min bicarbonate -0.0105 (-0.0122, -0.0087)
GBC and LR1. Another constellation of highly ranked features carries strong secondary
association with underlying kidney disease. These include medications used to treat
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consequences of decreased kidney function such as allopurinol, used to treat elevated
uric acid levels, and loop diuretics, used to reduce fluid retention, edema, and
hypertension. Highly ranked features associated with the presence of liver disease
(bilirubin) and associated treatment for both liver and heart disease (spironolactone)
were also identified. Moderate to advanced liver and heart disease are associated with
hepatorenal and cardiorenal syndromes, respectively, with resulting AKI (we even see
hepatobiliary diagnostic procedures associated with increased risk in LR1). Hemoglobin
is also identified, likely as an indicator of anemia resulting from renal pathology.
Interestingly, UN is often slightly preferred to sCr here, perhaps reflecting loss of muscle
mass due to catabolism during illness, with an associated lower creatinine production
blunting rise in sCr. UN is generally correlated with sCr, probably explaining the high
STD in the importances of both.
The LR1 coefficients reveal the sign of predictors. A number of features were
associated with lower probability of AKI by LR1, especially those generally associated
with populations having a lower incidence of kidney disease, including locations (labor
and delivery, emergency department), and diagnoses (injuries from trauma and
athletics). Interestingly, although with small coefficients, timing of discharge and
admission was identified as predictive. For example, prior Sunday discharge was
associated with a lower probability of AKI. This may be due to the common practice in
nursing homes and rehabilitation facilities to not accept weekend transfers, giving
complicated patients with a higher likelihood of AKI lower probability of Sunday
discharge. In contrast, weekend hospital admissions (Saturday admission) have a higher
number of traumatic injuries [75] and thus a lower number of conditions associated with
AKI (we see that diagnosis of traumatic injury is also present as a negative predictor).
In both GBC and LR1, “non-present” diagnoses and procedures were highly ranked
since history of few diagnoses and procedures reflect robust health.
Although UN and sCr would likely have been chosen to predict AKI, many of the
features studied here are novel representations. For example, rather than just a recent
UN, we include the number of abnormal lab flags for UN; rather than just an
at-admission sCr, we include the mean over hospitalizations of the sum of sCr per
hospitalization; rather than just presence of a loop diuretic on a medication list, we
include the actual number of administrations. Features of this form would probably not
have been collected a priori for AKI prediction, and their components are generally
hidden to providers. Many highly ranked features further depend on the behavior of
providers. This might suggest that to optimize EHR data it is important to capture
features that showcase provider behavior–such as testing or prescribing frequency.
Commonly used features such as “does this patient have comorbidity X” might be
better reformulated as “how many times in this patient’s history has a provider assigned
a code for comorbidity X”. The features are further enhanced by EHR-based analyses
(abnormal lab flagging).
Interestingly, features associated with AKI in prior studies that analyzed only data
available at admission were not necessarily detected as the best predictors here in
rehospitalized patients. For example, laboratory values dominated diagnosis codes, with
the exception of diagnoses related to CKD or AKI. We hypothesize that this may be
due to our focus on longitudinal measurements, inclusion of more candidate features,
the sparsity of ICD-9 codes, or perhaps correlation of diagnoses with laboratory
predictors (the latter provide more predictive information, being continuous-valued and
reliably collected variables). Laboratory features may also have been boosted by the
basis functions F , while the codes were generally just counted.
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HPLR1
All features with nonzero coefficients for HPLR1 are shown in Table 8 and the same for
RHPLR1 is shown in Supplement S29 Table. HPLR1 is especially interpretable. UN has
a large positive coefficient (note that there are two that are likely correlated and hence
have high STD). High glucose (endocrine or metabolic disorders) and potassium (renal
dysfunction) are also predictive along with discharge with assisted care (Home Health
Org.). Negative coefficients are on mean minimum hemoglobin, albumin, and calcium
(all resounding laboratory indicators of strong health and robust kidney function). Note
that every positive laboratory coefficient contains a maximum and every negative a
minimum.
Table 8. Coefficients of HPLR1.
HPLR1 (+) Mean (95% CI)
Age 0.2304 (0.229, 0.2318)
Max max urea nitrogen 0.1752 (0.1695, 0.1811)
Mean max urea nitrogen 0.1297 (0.1242, 0.1352)
Count Dx: AKI 0.0248 (0.0236, 0.026)
Mean max glucose 0.0001 (-0.0, 0.0002)
Mean max potassium 0.0001 (-0.0, 0.0002)
HPLR1 (-) Mean (95% CI)
Mean min hemoglobin -0.0931 (-0.0949, -0.0912)
Mean min albumin -0.0557 (-0.0573, -0.0541)
Mean min calcium -0.0001 (-0.0002, 0.0)
Comparison with features from Cronin et al. [16]
We can compare our features to those in Cronin et al. [16], where a random forest was
used to predict AKI stage 1+ (KDIGO stages 1, 2, or 3). In Cronin et al, we see strong
dependence on renal indicators (e.g., GFR, UN), labs indirectly associated with renal
function (Hemoglobin), heart failure, diuretics (loop, thiazides), and anti-hypertensives
such as angiotensin-converting enzyme inhibitors (ACEi), which is also reflected in our
findings. Although it is difficult to test rigorously, our study might suggest an
opportunity to more extensively incorporate laboratory values from the past as
predictors; Cronin et al. only used diagnoses and body mass index further than 365
days back and medications and temperature further than 90 days back.
We can also compare our LR1 with lasso results from Cronin et al. High odds ratios
in Cronin et al. were present in patients on antihypertensives (ACEi, angiotensin II
receptor blockers, thiazides, β-blockers), diagnoses associated with AKI (diabetes,
anemia, hyper and hypotension, peripheral vascular disease, HIV, cancer, and
rheumatoid arthritis), labs associated with renal function or injury (calcium,
hemoglobin, GFR, troponin, bilirubin), and antiobiotics (Sulfa). Again, we see many
features associated with renal function, renal medications, sepsis, or cardiovascular
dysfunction, which is also reflected in our findings. In our features, but not in Cronin et
al., we see discharge to home with outpatient care provided by a home health care
organization (e.g. visiting nurse, home physical therapy, home health aide), lab values
involving glucose, presence in the high risk labor and delivery unit or in the emergency
department, injury from athletics, assay of urine sodium, discharge with organization
care services, and marital status (possibly a proxy for age).
MGBC & MLR1
A substantial percentage of AKI is due to, or exacerbated by, medications. We were
thus interested in examining the medications in prior hospitalizations that might be
associated with AKI in subsequent hospitalizations. There were 927 medications
analyzed. The most important medication predictors are shown in Table 9. Here again,
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the combination of GBC and LR1 results is useful to put the identified features in
context. Medications used to treat chronic obstructive pulmonary disease, such as
albuterol and betamethasone, psychiatric conditions (respiridone, trazadone,
aripiprazole), or obstetric therapies (magnesium, pre-natal vitamins) had a negative
association with AKI. Our aim was to detect potentially modifiable risk factors, but it
is very difficult to disentangle confounders (e.g., Heparin might be associated with
thrombotic event prophylaxis, dextrose with diabetic ketoacidosis and malnutrition).
Most medications associated with high risk were actually given to protect the kidney
and most medications associated with low risk were given in the context of robust kidney
health. This analysis might be enhanced by somehow incorporating predictors from the
current hospitalization. We re-emphasize that no causal inference can be performed in
this study, but interesting findings include tacrolimus (known nephrotoxicity [76]),
midazolam (this association has been shown relative to propofol [77]), and oxycodone
(opioid nephrotoxicity is currently researched [78]). It is worth highlighting the
counter-intuitive finding that ibuprofen administration in prior hospitalizations is a
negative predictor for AKI. Probably this is because non-steroidal anti-inflammatory
medications (i.e. ibuprofen, ketorolac) are contraindicated in patients with elevated AKI
risk, and thus administration during a prior hospitalization is a clinical indicator for low
AKI risk. However, patients with extensive histories of ibuprofen use, given its
potentially deleterious effect on the kidney, should be monitored more closely for AKI.
Here however we analyze administrations, which, unlike use, reflect provider behavior.
Discussion
In this study, we investigated the feasibility of using prior hospitalizations to estimate
AKI risk at hospital re-entry. The general objective was to extract and compress
high-dimensional EHR information into a probability estimate specifically for
rehospitalized patients. Performance was assessed at the patient as well as
hospitalization level. Errors were also carefully analyzed to uncover gaps in predictive
performance, with comprehensive analysis of diagnosis, race, gender, age, utilization,
and method of AKI diagnosis. Increasing the l1 penalty produced a parsimonious and
interpretable HPLR1 whose features correspond to a striking physiological fingerprint
for AKI risk. Stability selection was performed to reinforce the results given the
colinearity of features. Other interesting predictors for AKI in rehospitalized patients
were found, including medications, which may enhance specification of statistical AKI
models and new investigations into modifiable risk factors. While such predictive
systems require extensive validation before clinical deployment, this work is a step
toward creating automated AKI predictions, specifically for rehospitalized patients.
With respect to generalizeability, we stress that we do not present a “model” for
AKI, but instead a mapping from input features to AKI probabilities. We reference a
distinction made in Schmueli, et al. [79] between explaining and predicting. Here, we do
the latter. We also reference a distinction made in Breiman, et al. [32] between models
and algorithms. Here, we use the latter. An explanatory model would require different
methods, especially with regard to model specification and dependencies in the data.
We also recommend that parameters be retuned on different data for use elsewhere
(“train locally”) as is commonly advised [16,70,80]. Thus, the systems presented here
are only valid in the population from which the training data were sampled, and even
there would require out-of-sample validation.
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Table 9. Feature importances/coefficients for MGBC and MLR1. Each
feature corresponds to the count of administrations of the medication over prior
hospitalizations.
MGBC Mean (95% CI)
Furosemide 0.0718 (0.0706, 0.0731)
Ibuprofen 0.0356 (0.035, 0.0361)
Sodium Chloride 0.0306 (0.0299, 0.0313)
Allopurinol 0.0245 (0.0239, 0.025)
Amlodipine Besylate 0.0237 (0.0232, 0.0242)
Oxycodone-Acetaminophen 0.0237 (0.023, 0.0243)
Spironolactone 0.0232 (0.0224, 0.024)
Heparin Sodium 0.0229 (0.0223, 0.0235)
Tacrolimus 0.0217 (0.0212, 0.0223)
Enoxaparin Sodium 0.0210 (0.0203, 0.0217)
Torsemide 0.0189 (0.0183, 0.0195)
Aspirin 0.0187 (0.0179, 0.0195)
Fentanyl Citrate 0.0183 (0.0171, 0.0194)
Dextrose 0.0180 (0.0175, 0.0186)
Levothyroxine Sodium 0.0154 (0.0148, 0.0161)
Piperacillin-Tazobactam In D 0.0145 (0.014, 0.0151)
Epoetin Alfa 0.0144 (0.0139, 0.0149)
Carvedilol 0.0133 (0.0125, 0.0141)
Hydralazine HCL 0.0128 (0.0121, 0.0135)
Sevelamer Carbonate 0.0119 (0.0111, 0.0126)
Metoprolol Tartrate 0.0113 (0.0107, 0.0118)
Docusate Sodium 0.0111 (0.0103, 0.0119)
Ceftriaxone Sodium In Dextrose 0.0104 (0.0097, 0.0111)
Pantoprazole Sodium 0.0103 (0.0095, 0.0111)
Metformin Hcl 0.0102 (0.0096, 0.0109)
Albuterol Sulfate Hfa 0.0099 (0.0092, 0.0105)
Vancomycin Hcl In Dextrose 0.0099 (0.0092, 0.0105)
Nephro-Vite 0.0090 (0.0084, 0.0096)
Magnesium Sulfate 0.0083 (0.0077, 0.0088)
Midazolam (Versed) 0.0083 (0.0076, 0.0091)
Glycopyrrolate 0.0081 (0.0072, 0.0088)
Paricalcitol 0.0071 (0.0062, 0.0081)
Cyclosporine Modified 0.0070 (0.0061, 0.0079)
Acetaminophen 0.0070 (0.0063, 0.0077)
Benazepril HCL 0.0068 (0.006, 0.0076)
Diltiazem HCL Er Beads 0.0067 (0.0057, 0.0076)
Labetalol HCL 0.0067 (0.006, 0.0073)
Losartan Potassium 0.0064 (0.0058, 0.0071)
Warfarin Sodium 0.0064 (0.0058, 0.007)
Albumin Human 0.0063 (0.0056, 0.0071)
MLR1 (+) Mean (95% CI)
Furosemide 0.1643 (0.161, 0.1677)
Heparin Sodium 0.1349 (0.1325, 0.1372)
Allopurinol 0.0947 (0.0912, 0.0982)
Enoxaparin Sodium 0.0883 (0.0857, 0.0911)
Piperacillin-Tazobactam In D 0.0809 (0.079, 0.0828)
Dextrose 0.0785 (0.0725, 0.0844)
Tacrolimus 0.0727 (0.0707, 0.0746)
Metoprolol Tartrate 0.0706 (0.0683, 0.0729)
Hydralazine HCL 0.0668 (0.0647, 0.0689)
Torsemide 0.0609 (0.0583, 0.0637)
Glucagon HCL (Rdna) 0.0545 (0.0483, 0.0606)
Ceftriaxone Sodium In Dextrose 0.0536 (0.0512, 0.056)
Epoetin Alfa 0.0531 (0.051, 0.0553)
Spironolactone 0.0530 (0.0501, 0.056)
Metoprolol Succinate 0.0500 (0.0483, 0.0517)
Sodium Chloride 0.0436 (0.0398, 0.0474)
Moxifloxacin HCL 0.0358 (0.0341, 0.0375)
Ciprofloxacin HCL 0.0347 (0.0326, 0.0368)
Fish Oil 0.0284 (0.0269, 0.0299)
Oxycodone HCL 0.0281 (0.026, 0.0303)
MLR1 (-) Mean (95% CI)
Ibuprofen -0.2765 (-0.2807, -0.2722)
Oxycodone-Acetaminophen -0.1575 (-0.1607, -0.1544)
Promethazine HCL -0.0914 (-0.0949, -0.0879)
Ondansetron -0.0791 (-0.082, -0.0761)
Hydroxyzine Pamoate -0.0707 (-0.0733, -0.0681)
Albuterol Sulfate Hfa -0.0576 (-0.0609, -0.0543)
Nicotine Polacrilex -0.0468 (-0.0501, -0.0434)
Tetanus-Diphth-Acell Pert -0.0393 (-0.0415, -0.0372)
Cyclobenzaprine HCL -0.0313 (-0.0335, -0.0292)
Classic Prenatal Vitamin -0.0312 (-0.0334, -0.0289)
Trazodone HCL -0.0300 (-0.0331, -0.0268)
Oxytocin -0.0288 (-0.0309, -0.0267)
Risperidone Microspheres -0.0264 (-0.0289, -0.024)
Risperidone -0.0231 (-0.0255, -0.0207)
Lorazepam (Ativan) -0.0207 (-0.0227, -0.0186)
Ketorolac Tromethamine -0.0207 (-0.0229, -0.0183)
Betamethasone Acetate & Sodium Phosphate -0.0119 (-0.0134, -0.0103)
Prenavite Protein Coated -0.0091 (-0.0116, -0.0064)
Aripiprazole -0.0067 (-0.008, -0.0053)
Etomidate -0.0065 (-0.0077, -0.0053)
Comparison to other AKI and EHR prediction studies
The state of the art in AKI prediction is the work of Cronin, et al. [16]. Direct
comparison of performance with their models is challenging for several reasons. First,
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they provide predictions at a different time. We provide an at-entry risk score while
Cronin et al. provides a risk score 48 hours post-admission. We therefore use only
features from prior hospitalizations while Cronin et al. uses features from the current
hospitalization (from the 48 hours between admission and prediction time) as well as
prior history. Specifically, Cronin et al. used preadmission body mass index and
preadmission diagnoses from -365 days to -24 hours and preadmission medications and
temperatures from -90 days to -24 hours. We did not have access to body mass index or
temperature, and the feature engineering required to extract other variables such as
medications was labor intensive, so even a comparison of our system with their
pre-admission system was not possible. Second, Cronin et al. focused specifically on
hospital-acquired AKI while we focused on hospital and community acquired AKI.
Third, we analyzed different cohorts. In Cronin et al., since prediction was made at 48
hours, all hospitalizations with duration less than 48 hours were excluded (roughly 1.9
million hospitalizations). In contrast, our study, in which a prediction is made at
hospital re-entry, applies to any patient regardless of length of stay. We, however also
excluded patients without prior hospitalizations (although we could give a prediction for
these patients with no information by simply using the baseline prevalence of AKI).
Therefore, in the space of all patients still present after 48 hours, the system in Cronin
et al. is more general; in the space of all rehospitalized patients, our system is more
general. Also, in Cronin et al., data was from Veterans Affairs hospitals and included
outpatient data; we only used inpatient data from a single hospital network, not just
veterans. Another similar study Kate et al. [27], analyzed strictly patients 65 years of
age and older, also making comparison difficult.
Outside of AKI, the state of the art in EHR prediction has generally been achieved
with RNN [81–83] or variations [84]. Here, we implemented an LSTM for sake of
comparison. The LSTM implemented here was not well optimized compared to those in
other studies, so it did not outperform the other systems. Nevertheless, LSTM has the
clear advantage of reducing dependence on feature engineering.
Interpretability
We do not recommend GBC, LR1, or LSTM for deployment because they are opaque.
These systems make the best predictions. However, GBC, LSTM, and LR1 analyze
thousands of features. In principle, a user must understand and check each of these
features in order to truly explain a prediction. Otherwise, GBC or LR1 could infer that
ibuprofen lowers AKI risk in an older patient with arthritis. Or, given so many
candidate predictors, GBC or LR1 might rely heavily on a feature whose relationship to
the response is borne of pure chance throughout the dataset and undetectable by internal
validation [85]. Some studies [8] have recommended that tools like GBC or LR1 only be
used for feature discovery, and rather that a tool similar to HPLR1 be deployed, even
with some reduction in predictive performance. The user, on whom the onus falls to
separate prediction from action [86], can more easily interpret HPLR1. Using fewer
features especially facilitates tracing an aberrant prediction back to, for example, a data
entry error. A parsimonious statistical model might even enable much needed
closed-form expressions for prediction intervals (e.g., since prediction variance increases
with risk). Thus, insights from this study can be used for specification of such a model.
We note, however, that only taking into account a few features potentially results in
a system that does not adjust for variables when it should. Further, a human provider
cannot analyze 1,500 features. Many of the features we analyze here are hidden from
the EHR user. A learning algorithm that analyzes a large amount of—sometimes
hidden—EHR data might thus be a useful complement. However, we cannot ignore the
benefits of parsimony, so recommend that both GBC (or LR1) and HPLR1 be used in
concert to give two separate risk scores.
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Limitations & future directions
The major limitation of this study is difficulty in validating the assumptions outlined in
the methods, especially the first assumption regarding interventions that flip labels.
Dependence on this assumption could be reduced by predicting sCr directly; since an
intervening provider is responding to sCr, the algorithm could stay one step ahead, or
by modifying the cost function to account for uncertainty in AKI status [87]. The last
assumption is also difficult to validate and might lead to a system that favors high
utilizers [88]. These difficulties arise from the fact that EHR data is not collected
explicitly for predictive modeling. We also list some methodological limitations and
future directions: the HP search space and the HP themselves were not conceived of
independently in each fold of nested CV, but instead set manually. Bias was preferred
to variance in choice of HP (and it was required that the test performance of the fold
used to select HP not be optimistic relative to the other folds, a constraint much more
easily fulfilled with higher bias HP). By doing so, however, the data were slightly
underfit, as evidenced by the error analysis, which essentially revealed undetected
patterns. This is especially apparent with respect to age. We strongly suspect that had
an ideal parameter search been achieved, or had HP that allowed higher variance been
permitted, the GBC could have detected most of these patterns, and the error analysis
would not have revealed such biases. This, however, might have increased risk of
overfitting. At least bias is possible to detect (as we have done) whereas overfitting can
be elusive. Given the high number of predictors (especially relative to the cases), GBC
and LR1 are likely overfit (not in the traditional sense, which can be detected via
internal validation) but to peculiarities of the entire dataset, impossible to determine
with internal validation alone. We however, via domain-expertise-guided evaluation of
features, consider this study to still contain insights of value to this prediction problem
and cohort.
Administrative codes are problematic predictors. Although codes may be embedded
or otherwise optimized as features [38,89], such approaches are not straightforward to
implement in a pipeline. Also, past AKI is a good predictor of future AKI. Numerous
reports suggest that codes have low sensitivity for AKI. Therefore, using code-based
AKI as a predictor is not ideal. AKI as a target was supplemented with sCr; AKI as a
predictor was not supplemented with sCr, however, as this would necessitate extensive
preprocessing of sCr trajectories in real time if deployed (time series models could take
care of this for free, however). For missing data imputation, more careful classification
of missingness and more sophisticated methods such as matrix completion should be
explored in the future. For laboratory values, Gaussian processes have also shown good
performance [83].
Codes are also problematic as targets. Although sCr-based diagnoses were used to
supplement codes, we noted high discrepancy between the two. Visual inspection
suggests that sCr for hospitalizations diagnosed by code but not sCr usually began
above normal and then decreased during the hospital stay, suggesting that an outpatient
reading, or even a high initial measurement, prompted code assignment. Without these
cases, our findings align with previous reports that codes are specific but not sensitive
for AKI. It was also apparent that errors were slightly higher in the cases diagnosed by
sCr but not by code. Another difficulty with diagnosis codes as labels is that they are
often assigned at the end of the hospitalization and therefore not time stamped. It is
impossible therefore to know when the AKI occurred during the hospitalization (i.e., we
do not distinguish between hospital- and community-acquired AKI). On a similar note,
because the majority of AKI codes were of “unspecified” severity, it was not possible to
distinguish severities of AKI. This issue could be alleviated by predicting sCr directly in
future work. Also relevant but not assessed is the performance of the systems as a
function of time as analyzed in [15]. For example, certain medications might wane in
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popularity or diseases might be seasonal. We hope to asssess this in the future and
analyze the effect of online training.
Conclusion
This study gives insight into the EHR-based AKI prediction problem in rehospitalized
patients. Our objective was to investigate the feasibility of predicting AKI in this cohort
as well as to analyze some interesting predictors. We trained several learning algorithms
and perform an in-depth error analysis, looking for specific patient groups for which
predictions might be poor. We also revealed novel predictors that could be used for
specification of a statistical model. We further focused on pharmaceutical predictors
that may be worth further exploration as modifiable risk factors. We consider this work
a step towards an automated, locally-trained tool that leverages sometimes hidden,
longitudinal EHR data to estimate AKI risk in rehospitalized patients without manual
ordering of tests, data collection, or data entry. Such an estimate could provide a prior
probability at the time of hospital re-entry to be used by an admitting provider or
another predictive algorithm.
Supporting Information
S1 File. Algorithm specifications.
GBC [90]: loss=deviance, learning rate=0.1, n estimators=100, subsample=1.0,
criterion=friedman mse, min samples split=150, min samples leaf=100, min weight
fraction leaf=0.0, max depth=2, min impurity split=1e-07, init=None, class
weight=balanced random state=random state, max features=None, verbose=0, max
leaf nodes=None, warm start=False, presort=auto
LR1 [91]: penalty=l1, dual=False, tol=0.0001, C=2e-3 (LR1) or 2e-4 (HPLR1), fit
intercept=True, intercept scaling=1, class weight=balanced, random state=random
state, solver=liblinear (uses coordinate descent), max iter=100, multi class=ovr,
verbose=0, warm start=False, n jobs=5
Lasso [92]: alpha=for diagnoses cases 0.015, for controls 10e-5; for other stratifiers, 0,
fit intercept=True, normalize=False, precompute=False, copy X=True, max iter=1000,
tol=0.0001, warm start=False, positive=False, selection=cyclic
Randomized Logistic Regression [93]: C=0.5 for RLR1 and 0.2 for RHPLR1, sample
fraction=0.74, n resampling=50 pipe to lasso with C=1, class weights=balanced
LSTM [94]: optimizer=adam, epochs=4, batch size=500, layer 1 hidden units=30,
layer 2 hidden units=20, dropout=random(0.25, 0.50, 0.75), iterations random
search=3, score random search=log loss
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S2 Fig. Metric distributions. Metric distributions over the 250 inner folds
are shown.
S3 Fig. Error distributions by diagnosis method. We show the distributions of
error, |yˆ − y| where y is a binary label and yˆ is the probability estimate, by diagnosis
method. “∨” corresponds to cases where diagnosis was made either by code or sCr; “∧”
corresponds to cases in which diagnosis was made by both code and sCr; “-” indicates a
set difference. Histograms have 1000 bins.
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S4 Fig. LR1 evaluation. ROC, Calibration, and PR curves for 50 iterations of
5-fold CV for LR1.
S5 Fig. ALR1 evaluation. ROC, Calibration, and PR curves for 50 iterations of
5-fold CV for the Anscombe LR1.
S6 Fig. RLR1 evaluation. ROC, Calibration, and PR curves for 50 iterations of
5-fold CV for the randomized LR1.
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S7 Fig. HPLR1 evaluation. ROC, Calibration, and PR curves for 50 iterations of
5-fold CV for the highly penalized LR1.
S8 Fig. RHPLR1 evaluation. ROC, Calibration, and PR curves for 50 iterations
of 5-fold CV for the randomized highly penalized LR1.
S9 Fig. WGBC evaluation. ROC, Calibration, and PR curves for 50 iterations of
5-fold CV for weighted GBC.
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S10 Fig. WGBC calibration. Observed hospitalization-level risk is plotted against
predicted risk (top) and patient-level mean observed risk against mean predicted risk
(bottom). In the scatter plots, alpha level is 0.05 and the red calibration curve
corresponds to all hospitalizations or to patients who had either mean risk over
hospitalizations of 1 or 0. The calibration curves are computed according to the
macro-averaged predicted output per hospitalization or patient over the 50 iterations of
5 fold CV (over 250 total folds). Ideal calibration is the dotted black diagonal. PO =
observed risk per hospitalization, PP = predicted risk per hospitalization, PO = mean
observed risk over hospitalizations, PP = mean predicted risk over hospitalizations.
S11 Fig. WGBC utilization. The mean and STD absolute error is shown as a
function of the number of hospitalizations. Patients were binned based on the number
of hospitalizations in the dataset and then, over bins, the mean error and STD of the
predictions were computed. Stratification by outcome is performed since it was earlier
established that the hospitalization:patient ratio is higher in cases than in controls.
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S12 Fig. WLR1 evaluation. ROC, Calibration, and PR curves for 50 iterations of
5-fold CV for weighted LR1.
S13 Fig. WHPLR1 evaluation. ROC, Calibration, and PR curves for 50
iterations of 5-fold CV for weighted HPLR1.
S14 Fig. SGBC evaluation. ROC, Calibration, and PR curves for 50 iterations of
5-fold CV for sampled GBC.
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S15 Fig. SLR1 evaluation. ROC, Calibration, and PR curves for 50 iterations of
5-fold CV for sampled LR1.
S16 Fig. SHPLR1 evaluation. ROC, Calibration, and PR curves for 50 iterations
of 5-fold CV for sampled HPLR1.
S17 Fig. RGBC evaluation. ROC, Calibration, and PR curves for 50 iterations of
5-fold CV for the RGBC using features from only the most recent hospitalization rather
than all available prior hospitalizations.
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S18 Fig. MGBC evaluation. ROC, Calibration, and PR curves for 50 iterations of
5-fold CV for the MGBC trained only on medications.
S19 Fig. MLR1 evaluation. ROC, Calibration, and PR curves for 50 iterations of
5-fold CV for the MLR1 trained only on medications.
S20 Fig. CLR evaluation. ROC, Calibration, and PR curves for 50 iterations of
5-fold CV for clinical LR.
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S21 Fig. LSTM evaluation. ROC, Calibration, and PR curves for 50 iterations of
5-fold CV for LSTM.
S22 Fig. NGBC evaluation. ROC, Calibration, and PR curves for 50 iterations of
5-fold CV for GBC trained on permuted response. The identity for the calibration curve
was hidden and the alpha value set to 1 for better visualization.
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S23 Fig. NGBC utilization. The mean and STD absolute error is shown as a
function of the number of hospitalizations. Patients were binned based on the number
of hospitalizations in the dataset and then, over bins, the mean error and STD of the
predictions were computed. Stratification by outcome is performed since it was earlier
established that the hospitalization:patient ratio is higher in cases than in controls.
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S24 Fig. NGBC prediction variance. The mean and standard deviation of
predicted probabilities are plotted over iterations (per hospitalization). Alpha=0.01 for
all plots.
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S25 Table. Regression results for error analysis. Shown is the choice of HP
Alpha and the train, validation, and test mean squared error (MSE) of the regression
from the fold in which Alpha was chosen.
Diagnosis Race Gender Age
AKI + (N=5,618) Alpha 0.015 0 0 0
MSE Train 0.021 0.32 0.032 0.030
Validation 0.022 0.31 0.031 0.028
Test 0.021 0.31 0.031 0.030
AKI - (N=84,395) Alpha 1e-5 0 0 0
MSE Train 0.005 0.007 0.007 0.006
Validation 0.005 0.007 0.007 0.006
Test 0.005 0.008 0.008 0.006
S26 Fig. GBC error by age. Alpha=0.01. The top (in red, lighter) are the cases
and the bottom (in blue, darker) are the controls.
S27 Fig. HPLR1 coefficient perturbation by utilization. Influence over
coefficients of HPLR1 vs. utilization is shown for each patient with two or more
hospitalizations. Distance between coefficient vectors was computed using the l1 norm.
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S28 Table. Feature importances/coefficients for RLR1. For laboratory
results, the first function is G, aggregation over hospitalizations, and the second is F ,
aggregation within a hospitalization; e.g., “mean max sCr” is the mean over
hospitalizations of the maximum sCr of each hospitalization.
RLR1 (+) Mean (95% CI)
Age 0.3533 (0.3511, 0.3555)
Count Dx: AKI 0.083 (0.0816, 0.0845)
Count discharges with home organization care services 0.0774 (0.0761, 0.0787)
Mean max glucose 0.0741 (0.0722, 0.0761)
Mean mean urea nitrogen 0.0682 (0.0665, 0.07)
Mean max urea nitrogen 0.0612 (0.0597, 0.0627)
Count Dx: CKD 0.0448 (0.043, 0.0467)
Mean max potassium 0.0429 (0.0415, 0.0443)
Mean min direct bilirubin 0.0394 (0.0367, 0.0421)
Max mean urea nitrogen 0.0381 (0.0371, 0.0391)
Count Px: Assay of urine sodium 0.0369 (0.0352, 0.0387)
Mean max sCr 0.0325 (0.0299, 0.0352)
Max max urea nitrogen 0.0317 (0.0308, 0.0327)
Max mean sCr 0.0258 (0.0233, 0.0284)
Max max sCr 0.0253 (0.0237, 0.0268)
Min min direct bilirubin 0.0231 (0.0201, 0.0262)
Mean mean sCr 0.0218 (0.0186, 0.025)
Min mean urea nitrogen 0.0194 (0.0156, 0.0231)
Min max urea nitrogen 0.019 (0.0155, 0.0224)
Max max glucose 0.0177 (0.0155, 0.02)
RLR1 (-) Mean (95% CI)
Mean min hemoglobin -0.0855 (-0.0882, -0.0826)
Mean min glomerular filtration rate-caucasian -0.0819 (-0.0846, -0.0793)
Max min hemoglobin -0.0737 (-0.0785, -0.069)
Mean min albumin -0.064 (-0.0653, -0.0627)
Mean mean albumin -0.0617 (-0.0631, -0.0603)
Mean min chloride -0.0579 (-0.0603, -0.0555)
Mean min calcium -0.0502 (-0.0545, -0.046)
Min min glomerular filtration rate-caucasian -0.0463 (-0.0477, -0.0449)
Marital status: single -0.0341 (-0.0394, -0.0287)
Min min hemoglobin -0.0239 (-0.0265, -0.0212)
Min min albumin -0.0181 (-0.0204, -0.0156)
Min min chloride -0.0177 (-0.0197, -0.0157)
Mean mean hemoglobin -0.0096 (-0.012, -0.0071)
Sum count abnormally high sCr -0.0045 (-0.0054, -0.0036)
Max mean albumin -0.003 (-0.0045, -0.0013)
Max max potassium -0.0027 (-0.0035, -0.0019)
Mean max albumin -0.0022 (-0.0033, -0.001)
Max min calcium -0.0021 (-0.0035, -0.0004)
Min mean albumin -0.0019 (-0.0028, -0.0011)
Count “non-present” DRGs -0.0015 (-0.0031, 0.0008)
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S29 Table. Coefficients of RHPLR1.
RHPLR1 (+) Mean (95% CI)
Age 0.3968 (0.3943, 0.4006)
Count Dx: AKI 0.132 (0.1302, 0.1339)
Max mean urea nitrogen 0.1181 (0.1153, 0.1208)
Max max urea nitrogen 0.0952 (0.0934, 0.0971)
Mean mean urea nitrogen 0.0837 (0.0797, 0.0879)
Max mean urea nitrogen 0.0754 (0.0737, 0.0771)
Mean max potassium 0.0565 (0.0501, 0.0628)
Sum count abnormally high sCr 0.0501 (0.0476, 0.0526)
Min mean urea nitrogen 0.0257 (0.0206, 0.0307)
Max max sCr 0.0198 (0.0151, 0.0243)
Count Dx: CKD 0.012 (0.0085, 0.0153)
Mean max sCr 0.0064 (0.0034, 0.0092)
Count Px: Assay of urine sodium 0.0052 (0.0027, 0.0075)
Sum count abnormally high glomerular filtration rate-caucasian 0.0047 (0.0036, 0.0059)
Mean max glucose 0.0033 (0.0005, 0.0055)
Count discharges with home organization care services 0.0027 (0.0004, 0.0045)
Count Px: Injection of furosemide or levetiracetam 0.0025 (0.0005, 0.0043)
Max max potassium 0.0012 (0.0, 0.0022)
Max count abnormally high sCr 0.0008 (-0.0001, 0.0014)
Sum count abnormally high glucose 0.0004 (-0.0004, 0.0007)
RHPLR1 (-) Mean (95% CI)
Mean min hemoglobin -0.1627 (-0.1675, -0.1577)
Mean min albumin -0.1286 (-0.1322, -0.125)
Mean mean albumin -0.0638 (-0.0695, -0.0582)
Max min hemoglobin -0.0341 (-0.0404, -0.028)
Min min hemoglobin -0.0307 (-0.036, -0.0254)
Mean min calcium -0.005 (-0.0077, -0.0019)
Min min albumin -0.0029 (-0.0046, -0.0009)
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